Lilly BioMedicines Head Ricks Tasked With Overseeing Growth Phase As Next CEO
Long-time CEO John Lechleiter, who led the company through a challenging period of enormous patent expirations, will step down at year's end.
You may also be interested in...
Musical Chairs: Lilly Leadership Changes Underscore Confidence In Donanemab Accelerated Approval
Oncology leader Anne White will oversee neuroscience and pain, while Bio-Medicines head Ilya Yuffa will take over for retiring Lilly International president; Loxo CEO will oversee entire oncology business.
Lilly Puts Down $200m To Use Dicerna's RNAi Platform For Metabolic, Neurological Diseases
Dicerna CEO tells Scrip the companies talked for two years and the collaboration came together as new Lilly R&D leadership looked to add novel approaches. Milestone fees of $350m per target for 10 or more targets value the deal at $3.7bn.
Lilly CEO ‘Encouraged’ By Trump Meeting As Volume – Not Prices – Drives 4Q Revenue Growth
Lilly’s new CEO David Ricks said he had confidence in the Trump Administration’s ability to understand and respond to the biopharma industry’s needs as well as address drug pricing concerns. The company’s fourth quarter earnings could insulate it from cost criticism, since sales volume drove revenue gains, not prices.